RCS - Rair Health Limited - RAIR Health joins the PathLAKE consortium

Green Cross HealthAnnouncement

15/08/2022 08:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220815:nRSO9074Va&default-theme=true

RNS Number : 9074V  Rair Health Limited  15 August 2022

August 15, 2022

 

RAIR HEALTH LIMITED

 

("RAIR" or "the Company")

 

RAIR Health joins the PathLAKE consortium as an Associate Member

 

RAIR Health Limited today announces it has joined the PathLAKE consortium as
an Associate Member, supporting its work in image-based AI and computational
pathology. RAIR's expertise is in the application of AI-driven biomedical
knowledge systems and feature extraction from medical images to derive
insights from clinical data. By joining the PathLAKE consortium RAIR furthers
its strategy of helping healthcare organisations apply AI to real-world data,
and to improve patient outcomes.

 

Led by University Hospitals Coventry and Warwickshire (UHCW) NHS Trust, the
PathLAKE consortium comprises some of the UK's leading digital and
computational innovators from the NHS, academia, and industry. By digitizing
five major NHS pathology labs and forming a computational hub, it has driven
AI innovation and created the world's largest repository of annotated,
digital, whole-slide images.

 

RAIR aims to help generate new insights using OCULAIR™, its state-of-the-art
biomedical knowledge system launched in May 2021. OCULAIR™ gives medical
researchers the ability to use AI to discover, interact and draw insights from
a vast store of structured and unstructured life science data. RAIR has also
built a clinical image processing workflow which, together with algorithms
written for OCULAIR™, can assist researchers in cellular pathology and
related image-based clinical fields.

 

Speaking about the consortium, Steve Cox CEO of RAIR, said:

"We are delighted to join the PathLAKE consortium and to help members build
the largest, most advanced resource for digital pathology. We recognise the
challenge of bringing complex datasets and images together to drive clinical
research, but we are confident that, working together with consortium members,
we can achieve this ambition".

 

For further information, please contact:

 

RAIR Health Limited

Steve Cox + 44 (0) 20 7924 2345

Chief Executive Officer

 

About RAIR Health Limited: RAIR is a London-based applied AI and clinical data
start-up. Its focus is on building a biomedical knowledge system to meet the
demand for insights, derived from real-world data, for life science research
and development. In particular, RAIR uses AI to extract insights from clinical
data including ophthalmological images. RAIR's therapeutic focus is on chronic
diseases that manifest in the eye, which include ophthalmological,
cardiovascular, rheumatological and neurological diseases.

 

Please visit www.rair.ai (http://www.rair.ai)

 

About PathLAKE: PathLAKE is one of a network of five Centres of Excellence in
digital pathology and medical imaging supported by a £50m investment from the
Data to Early Diagnosis and Precision Medicine strand of the Industrial
Strategy Challenge Fund, managed and delivered by UK Research and Innovation
(UKRI). Project Reference number (104689)

 

Please visit www.pathlake.org (http://www.pathlake.org)

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAUURORUKUWAAR